Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

Fig. 1

Flow chart. *In the 300 mg QD cohort, one patient had protocol violation and no exact administration time of BPI-9016M, the sparse PK data of four patients were analyzed based on population PK analysis without PK modeling, which were not included in PKAS. #In the 450 mg QD cohort, the sparse PK data of five patients were analyzed based on population PK analysis without PK modeling, which were not included in PKAS. †In the 600 mg QD cohort, one patient discontinued over two-week treatment of BPI-9016M due to the poor compliance, the sparse PK data of two patients were analyzed based on population PK analysis without PK modeling, which were not included in PKAS

QD quaque die, BID bis in die, TRAE treatment-related adverse event, FAS full analysis set, SS safety set, PKAS pharmacokinetics analysis set, PK pharmacokinetics

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us